Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

GSK Implements Genedata Biologics as Antibody Discovery Platform

Published: Thursday, June 12, 2014
Last Updated: Thursday, June 12, 2014
Bookmark and Share
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata BiologicsTM as a key R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.

The system records, manages, and processes data from GSK's diverse antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies, including proprietary ones. In addition, Genedata Biologics helps to improve data quality, improve efficiency through upload and export of instrument data, increase experimental throughput, and streamline workflows.

Genedata supports the deployment and roll-out of the Genedata Biologics system, its integration into GSK's R&D environment, and its use of Biopharm's high-throughput automation platforms. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats such as GSK's domain antibodies and other proprietary molecules and technologies.

As an integrated and scalable IT platform, Genedata Biologics makes it easy to share results across many groups involved in R&D projects. The system's built-in business logic supports the full diversity of GSK's complex and evolving antibody discovery processes.

"We are honored to have GSK, a global leader in biopharmaceuticals, chose Genedata Biologics as the platform to support their biopharmaceutical R&D processes," said Dr. Othmar Pfannes, CEO of Genedata. "The collaboration with GSK is another milestone on our path to establish Genedata Biologics worldwide as the platform of choice to streamline the discovery and development of novel biopharmaceuticals. We will continue to expand the platform to meet the quickly emerging new requirements in support of this highly innovative and important field."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Genedata Highlights Combination Screening and Surface Plasmon Resonance at SLAS 2015
Colloquium and tutorials on Combination Screening and SPR examine Genedata Screener as the platform for all plate-based screening experiments.
Wednesday, February 04, 2015
Takara Bio Selects Genedata Software to Automate and Standardize NGS Data Analysis
Genedata Expressionist® for Genomic Profiling helps Takara Bio to manage, process, and analyze large NGS datasets.
Wednesday, November 05, 2014
Exploring Innovations in SPR & Combination Screening
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.
Tuesday, August 26, 2014
Genedata Showcases Integrated Analysis & Image Management Solution for Phenotypic Screening
Regardless of instrument or application, Genedata Screener® for High Content Screening enables time-efficient workflow for analysis of high-content experiments
Friday, February 21, 2014
Genedata Announces New Data Analysis Platform for Next-Gen Oncology Drug Discovery
AstraZeneca and Genedata detail a data analysis platform for compound combination experiments in oncology and other therapeutic areas
Monday, February 03, 2014
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research
Leading clinical-research institute of the Robert Bosch Stiftung uses Genedata Expressionist for managing, processing, and interpreting clinical NGS data
Monday, January 27, 2014
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos